Outcomes in pediatric cardiac transplantation with a positive HLA cross-match

Pediatric Transplantation

Volumn 16, Issue 1, 2012, Pages 29-35

  Richmond, Marc E ^a   Hsu, Daphne T ^a   Mosca, Ralph S ^a   Chen, Jonathan ^a   Quaegebeur, Jan M ^a   Addonizio, Linda J ^a   Lamour, Jacqueline M ^a  

^a Columbia University ^*  (United States)

Author keywords

anti HLA antibody; HLA; outcome; pediatric heart transplant; survival

Indexed keywords

HLA ANTIGEN;

ARTICLE; CARDIOMYOPATHY; CHILD; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; RECIPIENT; REOPERATION; RETROSPECTIVE STUDY; TREATMENT INDICATION;

ADOLESCENT; ADULT; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROSPECTIVE STUDIES; REOPERATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84856012185     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01555.x     Document Type: Article

References (24)

1. Ratkovec RM, Hammond EH, O'Connell JB, et al., Outcome of cardiac transplant recipients with a positive donor-specific crossmatch-Preliminary results with plasmapheresis. Transplantation 1992: 54: 651-655.
2. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH,. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1993: 1: 60-65.
3. Betkowski AS, Graff R, Chen JJ, Hauptman PJ,. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant 2002: 21: 644-650. (Pubitemid 34626357)
4. Zangwill SD, Ellis TM, Zlotocha J, et al., The virtual crossmatch-A screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant 2006: 10: 38-41.
5. Scheinin SA, Radovancevic B, Kimball P, et al., Effect of IgM-positive crossmatches on survival in heart transplant recipients. Tex Heart Inst J 1995: 22: 67-71.
6. Richmond ME, Addonizio LJ, Hsu DT, et al., Cardiac retransplantation in high risk pediatric patients. Pediatr Transplant 2007: 11: 615-623. (Pubitemid 47174385)
7. Xydas S, Yang JK, Burke EM, et al., Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005: 24: 1289-1296. (Pubitemid 41247812)
8. Loh E, Bergin JD, Couper GS, Mudge GH Jr,. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. J Heart Lung Transplant 1994: 13: 194-201. (Pubitemid 24111707)
9. Jacobs JP, Quintessenza JA, Boucek RJ, et al., Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004: 78: 1703-1709. (Pubitemid 39423539)
10. Girnita AL, Webber SA, Zeevi A,. Anti-HLA alloantibodies in pediatric solid organ transplantation. Pediatr Transplant 2006: 10: 146-153.
11. Wright EJ, Fiser WP, Edens RE, et al., Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant 2007: 26: 1163-1169. (Pubitemid 350088510)
12. Almenar L, Maeso ML, Martinez-Dolz L, et al., Influence of HLA matching on survival in heart transplantation. Transpl Proc 2005: 37: 4001-4005. (Pubitemid 43015237)
13. Leech SH, Rubin S, Eisen HJ, et al., Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients. Clin Transpl 2003: 17 (Suppl 9): 17-26. (Pubitemid 36958180)
14. Kuhn MA, Jutzy KR, Deming DD, et al., The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol 2000: 36: 250-254. (Pubitemid 30466141)
15. Nicolas RT, Kort HW, Balzer DT, et al., Surveillance for transplant coronary artery disease in infant, child and adolescent heart transplant recipients: An intravascular ultrasound study. J Heart Lung Transplant 2006: 25: 921-927. (Pubitemid 44144591)
16. Hawkins JA, Breinholt JP, Lambert LM, et al., Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000: 119: 324-330. (Pubitemid 30091806)
17. Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE,. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg 2005: 79: 641-644. (Pubitemid 40186574)
18. John R, Lietz K, Burke E, et al., Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999: 100: II-229-II-235.
19. Meyer SR, Campbell PM, Rutledge JM, et al., Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. Eur J Cardiothorac Surg 2005: 27: 554-560. (Pubitemid 40409723)
20. Shaddy RE, Hunter DD, Osborn KA, et al., Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996: 94: 1063-1067. (Pubitemid 26292862)
21. Shaddy RE, Fuller TC, Anderson JB, et al., Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg 2004: 77: 1734-1739. (Pubitemid 38530014)
22. Shaddy RE, Fuller TC, Shaddy RE, Fuller TC,. The sensitized pediatric heart transplant candidate: Causes, consequences, and treatment options. Pediatr Transplant 2005: 9: 208-214. (Pubitemid 40476850)
23. Holt DB, Lublin DM, Phelan DL, et al., Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007: 26: 876-882. (Pubitemid 47371287)
24. Pollock-Barziv SM, Den Hollander N, Ngan B-Y, et al., Pediatric heart transplantation in human leukocyte antigen-sensitized patients: Evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007: 116: I-172-I-178.